---
title: "Fangsheng Pharmaceutical plans to acquire the marketing authorization for \"Compound Acetate Dexamethasone Cream.\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260394991.md"
description: "Fangsheng Pharmaceutical announced that it has signed a technology transfer contract with Yifan Pharmaceutical to acquire the marketing authorization for \"Compound Dexamethasone Acetate Cream.\" This move aims to enrich the company's product line, promote the development strategy of innovative traditional Chinese medicine, and is expected to bring new profit growth points to the company, enhancing its market competitiveness"
datetime: "2025-10-09T08:20:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260394991.md)
  - [en](https://longbridge.com/en/news/260394991.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260394991.md)
---

# Fangsheng Pharmaceutical plans to acquire the marketing authorization for "Compound Acetate Dexamethasone Cream."

According to the Zhitong Finance APP, Fangsheng Pharmaceutical (603998.SH) announced that on September 30, 2025, the company signed a "Technology Transfer (Trade Secret) Contract" with Yifan Pharmaceutical, deciding to acquire the marketing authorization for its "Compound Dexamethasone Acetate Cream" (including but not limited to the ownership of drug prescriptions, production processes, trade secrets, patents related to the target product, technical data, etc.).

Since the company established its development strategy of "becoming a health industry group centered on innovative traditional Chinese medicine," it has continuously increased its R&D investment and simultaneously reserved products with development potential through external purchases to enrich the company's product pipeline, thereby accelerating its development pace. After the completion of this acquisition, the company's dermatological drug category will be effectively expanded, and through the group's brand empowerment, it is expected to provide new profit growth points for the company. This acquisition of drug marketing authorization aligns with the company's development strategy, facilitates the integration and expansion of the industrial chain, and enhances the company's market competitiveness

### Related Stocks

- [603998.CN](https://longbridge.com/en/quote/603998.CN.md)

## Related News & Research

- [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md)
- [09:06 ETHarmony Comes to the Massachusetts State House as The Platters® Prepare Their Musical Love Letter to the World](https://longbridge.com/en/news/286918739.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [13:41 ETUT Haslam Marks Decade in Major International Ranking's Top Five U.S. Public Schools](https://longbridge.com/en/news/286804132.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)